tbuckley/cabot-search huggingface dataset:
A NEW METHOD FOR DEMONSTRATING SPIROCHETES BY LYMPH GLAND PUNCTURE
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE NATION'S HEALTH
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Offering Advance Directives
Authors: Kenneth D. Grant
Journal: Annals of Internal Medicine (1993)

Letters1 April 1993Offering Advance DirectivesKenneth D. Grant, MDKenneth D. Grant, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-7-199304010-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The study by Schneiderman and coworkers [1] is important because it was prospective and multidisciplinary. However, the results should be viewed cautiously. The research was completed nearly 2 years before the Patient Self-Determination Act was implemented, requiring that patients be advised at the time of hospital admission of their right to execute an advance directive. Few would deny that the inpatient setting is a suboptimal place to begin an initial discussion of discontinuation of treatment. However, the authors seem to imply that such issues should be excluded from hospital discussion simply because they have been previously raised ...REFERENCE1. Schneiderman LJ, Kronick R, Kaplan RM, Anderson JP, Langer RD. Effects of offering advance directives on medical treatments and costs. Ann Intern Med. 1992; 117:599-606. Google Scholar Author, Article, and Disclosure InformationAuthors: Kenneth D. Grant, MDAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1993Volume 118, Issue 7Page: 573-574KeywordsHospitalizationsInpatientsOutpatient clinicsOutpatientsPatient advocacyRetrospective studies ePublished: 15 August 2000 Issue Published: 1 April 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Molecular characterization and PCR diagnosis of Thailand deletion of α‐globin gene cluster
Authors: Tsang‐Ming Ko, Li‐Hui Tseng, Chuan‐Hong Kao, Yu‐Wan Lin, Hsiao‐Lin Hwa, Pi‐Mei Hsu, Shue‐Fun Li, Sou‐Ming Chuang
Journal: American Journal of Hematology (1998)
The diagnosis of art: Achilles Emperaire and spondyloepiphyseal dysplasia congenita
Authors: M. Ramachandran, J. K Aronson
Journal: Journal of the Royal Society of Medicine (2007)

Emperaire, an artist and a friend of Paul Ce ´zanne, was born in Aix-en-Provence in 1829, ten years after Ce ´zanne.Little is known about his life.In his early career, he moved frequently between Paris and Aix, working under the influence of the painter Thomas Couture and subsisting on only fifteen francs a month, often by copying pictures in the Louvre. 1 His artistic output was not prolific, but his paintings, particularly his nudes, show a fullness of form, an abundance of curves, and romantic inspiration similar to the works of Delacroix and Seurat.He repeatedly and unsuccessfully tried to exhibit his work at the Salon, the official art exhibition of the Acade ´mie des Beaux-Arts in Paris. 2 Ce ´zanne had an on-off relationship with Emperaire, at times helping him to gain employment, for example as a financial administrator for the Socie ´te ´des Artistes Franc ¸ais in Paris, but he frequently, and cruelly, did not support Emperaire through long periods of financial hardship.However, Ce ´zanne did appreciate his friend's work, and ten years before Emperaire's death in Aix in 1898 he wrote of him in a letter to Gasquet as follows: 'If I had been given the chance to ''realiser'', it is I who should have remained in my corner with some of the studio colleagues with whom we used to go to drink a stein of beer.I still have a good friend from those days; ah well, he didn't succeed, but just the same he was devilishly more painter than the bemedalled and decorated tramps that make one sweat.'
Long-Term and Tight Control of Gene Expression in Mouse Skeletal Muscle by a New Hybrid Human Transcription Factor
Authors: G ROSCILLI, C RINAUDO, M CIMINO, E SPORENO, S LAMARTINA, G CILIBERTO, C TONIATTI
Journal: Molecular Therapy (2002)

<h2>Abstract</h2> Diseases requiring frequent and lifelong injections of recombinant proteins would be more efficaciously treated by intramuscular delivery of genes encoding secretable proteins. However, the success of this approach largely depends on our capability to temporally regulate transcription of delivered genes. Therefore, we sought to generate a humanized transcription factor to regulate transgene expression in muscle. A novel 4-hydroxytamoxifen (4-OHT)-dependent transcriptional regulator (called HEA-3) was constructed by fusing in-frame the DNA binding domain of the human hepatocyte nuclear factor-1α (HNF1α), which is not expressed in muscle cells, a G(521)R mutant of the ligand binding domain of human estrogen receptor-α (ERα), and the activation domain derived from human nuclear factor-κB p65 subunit (NF-κB p65). We demonstrate that an artificial promoter containing multimeric HNF1α binding sites is silent in muscles and in cell lines that lack endogenous HNF1α. HEA-3 stimulated transcription from this target promoter in a stringent 4-OHT-dependent manner. The dynamic range of transgene regulation was high, because of the low basal activity and high inducibility of the system. <i>Ex vivo</i>, HEA-3 increased expression of the transfected reporter gene by more than 1000-fold in a ligand-dependent manner. <i>In vivo</i>, HEA-3 stimulated by more than 100-fold, the expression of secreted alkaline phosphatase after delivery as plasmid DNA into mouse muscles. Moreover, long-term modulation of the expression of intramuscularly delivered mouse erythropoietin was achieved in immunocompetent mice.
"THE SPIRITUAL ADVANCEMENT OF THE PHYSICIAN"
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents
Authors: M. Agulnik, A. M. Oza, G. R. Pond, L. L. Siu
Journal: Journal of Clinical Oncology (2005)

6006 Background: Trials of molecular targeted agents often require serial tumor bx to acquire tissues for correlative studies. Methods: Three complementary, self-administered questionnaires were circulated to: trial patients (TPs) who had previously undergone serial research-related bx, clinic patients (CPs) who had prior diagnostic but not research-related bx, and academic medical oncologists (MOs) in Canada. Questionnaires focused on 4 domains: demographics, bx-attributed risks, bx-provoked anxiety, and ethics of additional unrelated testing. Results: 10/14 (72%) TPs, 231/325 (71%) CPs and 127/206 (62%) MOs responded. Correlative testing of bx specimens was considered worthwhile by 96% of MOs. Clinical trials with mandatory bx were acceptable to 43% of CPs. Side effects from a previous bx, primarily pain, were reported by 30% of TPs and 35% of CPs. In assessing risks attributed to the bx, all 3 groups agreed that pain was the most acceptable, and bleeding the least. A 5–10% risk of a major bx complication was reported to be acceptable to 1% of MOs and 24% of CPs. Based on the Hospital Anxiety and Depression Scale, 30% of TPs reported anxiety prior to their initial research-related bx, while 56% of CPs reported anxiety prior to their previous diagnostic bx. For all patients, anxiety level decreased in 28%, remained the same in 65%, increased in 9%, after their bx (p<0.001). Over 90% of MOs felt the average patient would have borderline anxiety prior to their bx. Among the patients, 96% would authorize their samples for further unrelated research, 84% would agree to genetic testing and 93% wish to be informed of the results. Among the MOs, all considered it ethical to request for further unrelated research testing on the specimens, 83% would request genetic testing and 63% felt that patients should be informed of the results. Conclusions: Patients and MOs have different views about mandatory tumor bx. While nearly all MOs see the value in the bx, their threshold for acceptable risk is lower and they anticipate more associated anxiety than patients. Patients tend to tolerate the bx well, have average associated anxiety and readily allow their specimens to be tested for research purposes. No significant financial relationships to disclose.
Corrections to Kennard et al., Pham et al., Brent et al.
Journal: American Journal of Psychiatry (2019)

Our study demonstrates that peripartum depression is common among physician mothers.Less than half of the women in our study received formal treatment, with Asian subpopulations least likely to receive treatment.Most of these women reported stigmatizing attitudes regarding mental health conditions, and stigma was associated with decreased treatment utilization.Although our study is limited by reliance on self-reported depression instead of a validated instrument, only a third of women with instrument-validated depression will self-report depression (5).This study underscores the need for further research into the prevalence of peripartum depression, and barriers to treatment, among physician mothers.
Neuere Ergebnisse der Physiologie: In 22 Vorlesungen für Aerzte, Biologen und ältere Studierende. (Eine Ergänzung zu den Lehrbüchern der Physiologie).
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cecropia Moth
Authors: L. Jeffry Price
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Society Proceedings
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reduced Vascular Response to Angiotensin II in Secondary Hyperaldosteronism
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the authors
Authors: R. A. Rabinovich, R. Bastos, E. Ardite, L. Llinàs, M. Orozco-Levi, J. Gea, J. Vilaró, J. A. Barberà, R. Rodriguez-Roisin, J. C. Fernandez-Checa, J. Roca
Journal: European Respiratory Journal (2007)
Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial
Authors: W. D. Weaver
Journal: JAMA (1993)

<h3>Objective.</h3> —To determine the effect of prehospital-initiated vs hospital-initiated treatment of myocardial infarction on clinical outcome. <h3>Design.</h3> —Randomized, controlled clinical trial. <h3>Setting.</h3> —Multicenter study involving 19 hospitals and all paramedic systems in the Seattle, Wash, metropolitan area. <h3>Patients.</h3> —A total of 360 patients with symptoms for 6 hours or less, no risk factors for serious bleeding, and ST-segment elevation were selected by paramedics and a remote physician for inclusion into the trial. They represented 4% of patients with chest pain who were screened and 21% of those with acute infarction. <h3>Interventions.</h3> —Patients were allocated to have aspirin and alteplase treatment initiated before or after hospital arrival. Intravenous sodium heparin was administered to both groups in the hospital. <h3>Main Outcome Measure.</h3> —The primary endpoint was a ranked composite score (combining death, stroke, serious bleeding, and infarct size). The relation between time to treatment and outcome (composite score, infarct size, ejection fraction, and mortality) was also assessed. <h3>Results.</h3> — Initiating treatment before hospital arrival decreased the interval from symptom onset to treatment from 110 to 77 minutes (<i>P</i>&lt;.001). Although more patients whose therapy was initiated before hospital arrival had resolution of pain by admission (23% vs 7%;<i>P</i>&lt;.001), there were no significant differences in the composite score (<i>P</i>=.64), mortality (5.7% vs 8.1%), ejection fraction (53% vs 54%), or infarct size (6.1% vs 6.5%). A secondary analysis of time to treatment and outcome showed that treatment initiated within 70 minutes of symptom onset was associated with better outcome (composite score,<i>P</i>=.009; mortality, 1.2% vs 8.7%,<i>P</i>=.04; infarct size, 4.9% vs 11.2%,<i>P</i>&lt;.001; and ejection fraction, 53% vs 49%,<i>P</i>=.03) than later treatment. Identification of patients eligible for thrombolysis by paramedics reduced the hospital treatment time from 60 minutes (for patients not in the study) to 20 minutes (for study patients allocated to begin treatment in the hospital). <h3>Conclusion.</h3> —There was no improvement in outcome associated with initiating treatment before hospital arrival; however, treatment within 70 minutes of symptom onset—whether in the hospital or in the field—minimized the infarct process and its complications. (<i>JAMA</i>. 1993;270:1211-1216)
Medicaid’s Impact on Overdose Rates
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Return on INVEST—Correction
Authors: Srinivasan Madhusudan, Gae ¨l Deplanque, Jeremy Braybrooke, Emma Cattell, Marian Taylor, Pat Price, Marie Tsaloumas, Niall Moore, Susan Huson, Chris Adams, Adrian Harris
Journal: JAMA (2004)

diological appearance of his tumors remained stable for 14 months.This patient's pretreatment VEGF level of 91 pg/mL, increased to 116 pg/mL at 6 months.Serial measurements of plasma levels of VEGF were available for 2 of the 4 patients who did not have a clinical response.In 1 patient, VEGF level decreased from 166 pg/mL to 51 pg/mL by the end of treatment, but in the other it increased from 15 pg/mL to 26 pg/mL.Common adverse effects included headache, vomiting, nausea, fatigue, diarrhea, arthralgia, and pruritus.Treatment was discontinued in 1 patient because of severe uncontrollable pruritus.Comment.We found that SU5416 was associated with improved clinical status in 2 of 6 patients with advanced VHL disease.Although it was also associated with reduction in serum levels of VEGF in some patients, this did not correlate with clinical response.Recovery of visual function with SU5416 has been reported in a patient with VHL disease and optic nerve hemangioblastoma 8 and in another patient with retinal hemangioblastoma and associated cystoid macular edema. 9We found evidence for the regression of a retinal lesion, as well as possible clinical benefit of SU5416 in lesions outside the retina.Further evaluation of inhibitors of VEGF receptor 2 in VHL disease is needed.
Antibody-Coated Bacteria in Urine
Journal: New England Journal of Medicine (1976)

Technical methods globulin containing cells.We do not understand the processes involved, but this seems to be a useful procedure.References 1 Pinkus GS, Said JW. Specific identification of intracellular immunoglobulin in paraffin sections of multiple myeloma and macroglobulinaemia using an immunoperoxidase technique.